applsci-logo

Journal Browser

Journal Browser

Natural Products and Drug Discovery for Neurodegenerative Diseases

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2614

Special Issue Editors


E-Mail Website
Guest Editor
Indian Scientific Education and Technology (ISET) Foundation, Lucknow 226002, India
Interests: neuroscience; Alzheimer's disease; natural products; therapeutic; drug discovery; oxidative stress; nutraceuticals
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
School of Bioengineering and Biosciences, Lovely Professional University, Phagwara 144402, Punjab, India
Interests: diabetes; neurodegeneration; hepatotoxicity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Research Institute for Neurosciences & Medicine, 630117 Novosibirsk, Russia
Interests: neuroscience; neuropharmacology; neurodegenerative disorders; traumatic brain injury; animal models; behavior; neurogenomics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Department of Physiology, Johann-Friedrich-Blumenbach-Institute for Zoology and Anthropology, Faculty of Biology Georg August University Göttingen, Göttingen and Goettingen Research Campus, Göttingen, Am Türmchen 3, D-33332 Gütersloh, Germany
Interests: aging; amino acids; antioxidants; inflammaging; melatonin; product development; tryptophan
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases (NDs) constitute a large group of pathological conditions, characterized by a progressive loss of neuronal cells, which compromise motor and/or cognitive functions. The most common NDs are Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Huntington’s disease (HD). The causes of these pathologies are multifactorial and not fully understood, but it is well known that factors related to aging and to the overproduction of free radical and reactive oxygen species lead to oxidative stress and to cell death, which are extremely related. Whereas oxidative stress plays an unquestionable and central role in NDs, the control of free radicals and reactive oxygen species levels represents an interesting and promising strategy to delay neurodegeneration and attenuate the associated symptoms.

In this context, several natural bioactive compounds isolated from plants, fungi, and algae, among others, which present antioxidant properties, including vitamins C and E, anthocyanins, and phenolic compounds, are extensively described as potential palliative agents of neurodegenerative symptoms. In vitro and in vivo studies, performed with extracts and fractions of plants and with isolated natural bioactive compounds, provide evidence of the role of these substances in the modulation of the cellular redox balance and in the reduction in the formation of reactive oxygen species originating from oxidative stress, thereby demonstrating their great value as antioxidant agents and cellular protectors.

In antiquity, diverse natural compounds were used to treat several ailments and chronic diseases and were recognized for their therapeutic properties in folklore medicine. These compounds have heterogeneous chemical structure and varied pharmacological activity, being useful in the treatment of diseases of high complexity such as Parkinson’s disease, Alzheimer's disease, and others. Notwithstanding, at the present time, commercial drugs are in many cases aspecific and present side effects that increase pain or malaise in patients. It has been observed that several polyphenolic compounds derived from different natural herbs/plants are associated with successful medical treatment in various human diseases, including neurodegenerative diseases. Thus, extensive use of natural compounds might be a key to generating effective drugs against the treatment of different neurodegenerative diseases. Many researchers are studying to find out the role of different natural compounds and are interested in discovering new natural products with effective medical applications. The interest in these drugs is especially related to the treatment of neurodegenerative disorders such as Alzheimer's disease, Parkison’s disease, ALS, etc. In recent times, some phytodrugs have been methodically tested in in vivo and in vitro models of AD and also in clinical trials. Ginkgo biloba, Curcuma longa, Withania somnifera, and Angelica sinensis extracts have been found to show neuroprotective properties against several human neurodegenerative diseases.

In this Special Issue, we invite researchers to contribute original research and review articles that will help to elucidate the therapeutic potential of natural compounds against various human neurodegenerative disease. We encourage the submission of studies dealing with the use of natural or herbal approaches describing the role of respective compounds as a drug candidate in different neurodegenerative diseases.

Potential topics include but are not limited to the following:

  • Different natural compounds with drug therapeutic potential;
  • Neuroprotective activity of herbal compounds against different neurodegenerative diseases;
  • Antioxidant properties of the natural compounds in various neurodegenerative diseases;
  • Mechanism of actions of different natural drugs used in the treatment of different human neurodegenerative diseases;
  • Mechanism and action of natural compounds involved in oxidative stress management in neurodegenerative diseases;
  • Improved cognitive functions in different animal models by the treatment of herbal extracts.

Dr. Sandeep Singh
Dr. Mahendra P. Singh
Dr. Maria Tikhonova
Dr. Burkhard Poeggeler
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • neurodegenerative diseases
  • drug delivery system
  • neuroprotection
  • antioxidative natural compounds

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 4800 KiB  
Article
The Mixture of Gastrodia elata and Glycyrrhiza uralensis Attenuates Scopolamine-Induced Cognitive Disorder
by Ji-Hyun Lee, Sung-Wook Kim, Seong-Hoon Lee, Jae-Yeon Cho, Su-Ha Hwang, Won-Woo Lee, Jang-Won Lee, Dae-Ki Kim and Yong-Deok Jeon
Appl. Sci. 2023, 13(6), 3690; https://doi.org/10.3390/app13063690 - 14 Mar 2023
Cited by 2 | Viewed by 2044
Abstract
Background: Cognitive disorders are symptoms of degenerative neuronal diseases such as Alzheimer’s disease (AD). This study evaluated the effects of a mixture of Gastrodiae elata (GE) and Glycyrrhizae uralensis (GU) (GGW) on scopolamine-treated cognitive function disorders in vivo. Methods: To induce memory impairment [...] Read more.
Background: Cognitive disorders are symptoms of degenerative neuronal diseases such as Alzheimer’s disease (AD). This study evaluated the effects of a mixture of Gastrodiae elata (GE) and Glycyrrhizae uralensis (GU) (GGW) on scopolamine-treated cognitive function disorders in vivo. Methods: To induce memory impairment and cognitive disorder, C57BL/6 mice were intraperitoneally administered scopolamine. In the experimental period, the Y-maze, passive avoidance, and water maze tests were carried out to measure the ameliorative effect of GGW on cognitive function disorder. The expression of amyloid-β (Aβ), brain-derived neurotrophic factor (BDNF), and acetylcholinesterase (AChE) in the hippocampal tissues were measured. In addition, to assess the effect of GGW on brain tissue, tissues were stained using hematoxylin and eosin (H&E). Results: GGW treatment improved latencies in the Y-maze, water maze, and passive avoidance tests compared with scopolamine treatment alone. GGW administration downregulated Aβ and AChE expression. In addition, BDNF expression was upregulated by GGW administration. Conclusion: These results suggest that GGW ameliorates impaired cognitive function in a scopolamine-induced mouse model. In addition, GGW could control the pathway of scopolamine-induced cognitive disorders by regulating Aβ, AChE, and BDNF. These results suggest that GGW could be used as a treatment agent for cognitive dysfunction. Full article
(This article belongs to the Special Issue Natural Products and Drug Discovery for Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop